These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 17988723)

  • 21. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
    Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
    MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies.
    Miura N; Kanamori Y; Takahashi M; Sato R; Tsukamoto T; Takahashi S; Harada T; Sano A; Shomori K; Harada T; Kigawa J; Ito H; Terakawa N; Hasegawa J; Shiota G
    Oncol Rep; 2007 Mar; 17(3):541-8. PubMed ID: 17273731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-11 receptor expression in primary ovarian carcinomas.
    Campbell CL; Guardiani R; Ollari C; Nelson BE; Quesenberry PJ; Savarese TM
    Gynecol Oncol; 2001 Feb; 80(2):121-7. PubMed ID: 11161848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of transforming growth factor alpha mRNA in benign and malignant tissues derived from gynecologic patients with various proliferative conditions.
    Xynos FP; Klos DJ; Hamilton PD; Schuette V; Fernandez-Pol JA
    Anticancer Res; 1992; 12(4):1115-20. PubMed ID: 1323947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.
    Song JY; Chen KY; Kim SY; Kim MR; Ryu KS; Cha JH; Kang CS; MacLaughlin DT; Kim JH
    Int J Oncol; 2009 Jun; 34(6):1583-91. PubMed ID: 19424576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
    Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
    Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adrenomedullin (AM) and AM receptor type 2 expression is up-regulated in prostate carcinomas (PC), and AM stimulates in vitro growth of a PC-derived cell line by enhancing proliferation and decreasing apoptosis rates.
    Mazzocchi G; Malendowicz LK; Ziolkowska A; Spinazzi R; Rebuffat P; Aragona F; Ferrazzi E; Parnigotto PP; Nussdorfer GG
    Int J Oncol; 2004 Dec; 25(6):1781-7. PubMed ID: 15547717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
    Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
    Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression.
    Melichar B; Konopleva M; Hu W; Melicharova K; Andreeff M; Freedman RS
    Gynecol Oncol; 2004 Apr; 93(1):149-54. PubMed ID: 15047229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
    Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins AC; Li Y
    Gynecol Oncol; 2007 Jun; 105(3):695-702. PubMed ID: 17368732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
    Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
    Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
    Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
    Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival.
    Thouënnon E; Pierre A; Tanguy Y; Guillemot J; Manecka DL; Guérin M; Ouafik L; Muresan M; Klein M; Bertherat J; Lefebvre H; Plouin PF; Yon L; Anouar Y
    Endocr Relat Cancer; 2010 Sep; 17(3):637-51. PubMed ID: 20483910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Peroxisome proliferator activated receptor gamma coactivator-1 induces apoptosis in human epithelial ovarian cancer cells].
    Ba Y; Zhang Y; Zhang CY
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1430-3. PubMed ID: 17785072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene.
    Tao Q; Fujimoto J; Men T; Ye X; Deng J; Lacroix L; Clifford JL; Mao L; Van Pelt CS; Lee JJ; Lotan D; Lotan R
    J Natl Cancer Inst; 2007 Nov; 99(22):1668-82. PubMed ID: 18000218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells.
    Bhatt AS; Takeuchi T; Ylstra B; Ginzinger D; Albertson D; Shuman MA; Craik CS
    Biol Chem; 2003 Feb; 384(2):257-66. PubMed ID: 12675519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.
    Jones MB; Houwink AP; Freeman BK; Greenwood TM; Lafky JM; Lingle WL; Berchuck A; Maxwell GL; Podratz KC; Maihle NJ
    J Soc Gynecol Investig; 2006 May; 13(4):304-11. PubMed ID: 16697948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
    Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
    Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer.
    Yuan QA; Simmons HH; Robinson MK; Russeva M; Marasco WA; Adams GP
    Mol Cancer Ther; 2006 Aug; 5(8):2096-105. PubMed ID: 16928831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.